| First Author | Mackman N | Year | 2018 |
| Journal | J Clin Invest | Volume | 128 |
| Issue | 9 | Pages | 3747-3749 |
| PubMed ID | 30102257 | Mgi Jnum | J:266918 |
| Mgi Id | MGI:6257227 | Doi | 10.1172/JCI122881 |
| Citation | Mackman N (2018) The red blood cell death receptor and thrombosis. J Clin Invest 128(9):3747-3749 |
| abstractText | RBCs are the most abundant circulating cells in humans and typically comprise 35% to 45% of the blood volume (hematocrit). Anemia is associated with an increase in bleeding, and epidemiological studies have shown an association between an elevated hematocrit and thrombosis. RBCs may contribute to hemostasis and thrombosis via mechanisms that include platelet margination leading to an increase in the near-wall platelet concentration, blood viscosity, thrombin generation, and platelet activation. In this issue of the JCI, Klatt et al. report that binding of the Fas ligand FasL on the surface of platelets to its cognate receptor FasR on the surface of RBCs increases thrombin generation in vitro and thrombosis in mouse models. This represents a new mechanism by which RBCs contribute to thrombosis. |
